BioPharma Resources

Investigational drug · Phase 3

MTBVAC

Also called: BBV169

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Tuberculosis, Tuberculosis (TB).

Phase 3

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

9

Any phase or sponsor naming "MTBVAC"

First trial start

2022

Oct 17, 2022

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "MTBVAC", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Tuberculosis
  • Tuberculosis (TB)

Approved drugs for the same conditions: Tuberculosis · Infectious disease and vaccines

Largest trials

Live from ClinicalTrials.gov: studies naming "MTBVAC" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 53 on PubMed

Also in development for Tuberculosis

  • BCGPhase 38 trials

    ImmunityBio, Inc. · Non-muscle Invasive Bladder Cancer (NMIBC), Papillary-Only Non-muscle-invasive Bladder Cancer, Tuberculosis

  • TB-PPDPurified Protein Derivative of TuberculinPhase 32 trials

    Chengdu CoenBiotech Co., Ltd · Tuberculosis, Latent Tuberculosis Infection

  • DelamanidPhase 22 trials

    WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

  • BNT164a1Phase 21 trial

    BioNTech SE · Tuberculosis

  • BNT164b1Phase 21 trial

    BioNTech SE · Tuberculosis

  • BTZ-043Phase 21 trial

    GSK · Tuberculosis

  • GSK3036656Phase 21 trial

    GSK · Tuberculosis

  • JDB0131Phase 21 trial

    WestVac Biopharma Co., Ltd. · Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.